AAFP News |
FDA Warns of Amputation Risk Linked to Newer Diabetes Drug
AAFP News Canagliflozin is a member of the class of medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. Marketed as single-ingredient products or in combination with other diabetes drugs such as metformin, SGLT2 inhibitors are FDA-approved ... |
Social Plugin